LLY Feb 2023 290.000 call
| Previous Close | 40.91 |
| Open | 35.08 |
| Bid | 43.55 |
| Ask | 47.05 |
| Strike | 290.00 |
| Expire Date | 2023-02-17 |
| Day's Range | 35.08 - 40.91 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 119 |
- Simply Wall St.
Eli Lilly and Company (NYSE:LLY) is largely controlled by institutional shareholders who own 85% of the company
Every investor in Eli Lilly and Company ( NYSE:LLY ) should be aware of the most powerful shareholder groups. With 85...
- Reuters
Drug companies face COVID cliff in 2023 as sales set to plummet
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.
- Reuters
FOCUS-Drug companies face COVID cliff in 2023 as sales set to plummet
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE , Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.
